Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

[cafead]

via Topline data from the Phase III NATALEE study showed Novartis’ Kisqali (ribociclib) met its primary endpoint, reducing the risk of recurrence in early breast cancer, the company announced Monday.

article source